Skip to content
lifestyle.thedishh.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
NOVO NORDISK INC.
Novo post hoc analysis finds Wegovy® 2.4 mg was associated with improvements in liver markers in adults with MASH with liver scarring and a BMI less than 27 kg/m2, presented at The Liver Meeting® (AASLD) 2026
November 8, 2026
Novo real-world studies link Wegovy® 2.4 mg to reductions in liver enzymes, weight, and blood sugar in adults with MASH at The Liver Meeting® (AASLD) 2026
November 6, 2026
Novo to present new CagriSema and Wegovy® data at ObesityWeek® 2026, including data on treatment experience with Wegovy® pill in the real world
October 29, 2026
Novo to present new liver data across Wegovy 2.4 mg and investigational efruxifermin at The Liver Meeting® (AASLD) 2026
October 28, 2026
Novo’s CagriSema was associated with 25% weight loss on average for women in a post hoc analysis of REDEFINE 1 presented at The Menopause Society Annual Meeting
October 21, 2026
People switching from weight-loss injections to Novo’s Wegovy® pill lost 4.1% body weight on average after three months, according to real-world data presented at EASD2026
September 30, 2026
Novo Nordisk advances cardiometabolic pipeline with new data featuring CagriSema and zenagamtide at the American Diabetes Association’s 2026 Scientific Sessions
May 27, 2026